Lori A Leslie
Overview
Explore the profile of Lori A Leslie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Harley N, Leslie L
Health Phys
. 2023 Mar;
124(6):475-477.
PMID: 36880974
Leukemia was the first medically observed human cancer related to ionizing radiation in the 1945 follow-up study of atomic bomb survivors. The bone exposure and dose calculated here are based...
12.
Della Pia A, Kim G, Ip A, Ahn J, Liu Y, Kats S, et al.
PLoS One
. 2022 Dec;
17(12):e0266584.
PMID: 36454941
Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma...
13.
Leslie L, Gangan N, Tan H, Huang Q
Curr Med Res Opin
. 2022 Oct;
38(12):2149-2161.
PMID: 36205521
Objectives: To evaluate the trend in cytogenetic/molecular testing rate in chronic lymphocytic leukemia (CLL) and assess the clinical and economic burden of first-line (1 L) treatment with chemoimmunotherapy (CIT) by...
14.
Della Pia A, Zhao C, Jandir P, Gupta A, Batistick M, Kim G, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077782
Lymphoma patients are at greater risk of severe consequences from COVID-19 infection, yet most reports of COVID-19-associated outcomes were published before the advent of COVID-19 vaccinations and monoclonal antibodies (mAbs)....
15.
Roeker L, Feldman T, Soumerai J, Falco V, Panton G, Dorsey C, et al.
Clin Cancer Res
. 2022 Jul;
28(18):3958-3964.
PMID: 35852793
Purpose: Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an "add on" approach for...
16.
Petrillo A, Ip A, Della Pia A, Gill S, Zenreich J, Gutierrez M, et al.
Hemasphere
. 2022 Jun;
6(6):e719.
PMID: 35747844
No abstract available.
17.
Huang Q, Deering K, Harshaw Q, Leslie L
Adv Ther
. 2022 May;
39(7):3292-3307.
PMID: 35608754
Introduction: Certain genetic features in chronic lymphocytic leukemia (CLL) are associated with inferior outcomes after chemoimmunotherapy (CIT). This retrospective study evaluated treatment patterns and clinical outcomes of patients with CLL,...
18.
Jacobson C, Chavez J, Sehgal A, William B, Munoz J, Salles G, et al.
Lancet Oncol
. 2021 Dec;
23(1):91-103.
PMID: 34895487
Background: Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma....
19.
Locke F, Miklos D, Jacobson C, Perales M, Kersten M, Oluwole O, et al.
N Engl J Med
. 2021 Dec;
386(7):640-654.
PMID: 34891224
Background: The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. Methods: In this international, phase 3 trial, we randomly...
20.
Leslie L
Curr Treat Options Oncol
. 2021 Oct;
22(12):111.
PMID: 34694508
When selecting therapy for patients with indolent non-Hodgkin lymphoma (iNHL) including follicular (FL), marginal zone (MZL), small lymphocytic (SLL), and lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM), there are several factors to...